The -2518A>G promoter polymorphism in the CCL2 gene is not associated with systemic sclerosis susceptibility or phenotype: Results from a multicenter study of European Caucasian patients

Human Immunology

Volumn 70, Issue 2, 2009, Pages 130-133

  Radstake, Timothy R D J ^a   Vonk, Madelon C ^a   Dekkers, Marieke ^a   Schijvenaars, Mascha M V A P ^a   Treppichio, William L ^b   Lafyatis, Robert ^c   Riemekasten, Gabriela ^d   van den Hoogen, Frank ^e   Coenen, Marieke J H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

^c BOSTON MEDICAL CENTER   (United States)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e Charité University Medicine Berlin ^*  (Netherlands)

Author keywords

CCL2; Single nucleotide polymorphism; Systemic sclerosis

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CENTROMERE ANTIBODY; DNA TOPOISOMERASE ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CAUCASIAN; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC SUSCEPTIBILITY; GENOTYPE; GERMANY; HUMAN; INFORMED CONSENT; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC SCLEROSIS;

ADULT; AGED; ALLELES; CHEMOKINE CCL2; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; SCLERODERMA, SYSTEMIC; YOUNG ADULT;

EID: 59649084868     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2008.10.012     Document Type: Article

References (24)

1. Distler O., Pap T., Kowal-Bielecka O., Meyringer R., Guiducci S., Landthaler M., et al. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: Role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum 44 (2001) 2665-2678
2. Hasegawa M., Sato S., and Takehara K. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1alpha (MIP-1alpha) and MIP-1beta) in patients with systemic sclerosis: MCP-1 and MIP-1alpha may be involved in the development of pulmonary fibrosis. Clin Exp Immunol 117 (1999) 159-165
3. Loyd J.E., Slovis B., Phillips III J.A., Butler M.G., Foroud T.M., Conneally P.M., and Newman J.H. The presence of genetic anticipation suggests that the molecular basis of familial primary pulmonary hypertension may be trinucleotide repeat expansion. Chest 111 6 Suppl (1997) 82S-83S
4. Rollins B.J. Monocyte chemoattractant protein 1: A potential regulator of monocyte recruitment in inflammatory disease. Mol Med Today 2 (1996) 198-204
5. Gharaee-Kermani M., McCullumsmith R.E., Charo I.F., Kunkel S.L., and Phan S.H. CC-chemokine receptor 2 required for bleomycin-induced pulmonary fibrosis. Cytokine 24 (2003) 266-276
6. Moore B.B., Paine III R., Christensen P.J., Moore T.A., Sitterding S., Ngan R., et al. Protection from pulmonary fibrosis in the absence of CCR2 signaling. J Immunol 167 (2001) 4368-4377
7. Kimura M., Kawahito Y., Hamaguchi M., Nakamura T., Okamoto M., Matsumoto Y., et al. SKL-2841, a dual antagonist of MCP-1 and MIP-1 beta, prevents bleomycin-induced skin sclerosis in mice. Biomed Pharmacother 61 (2007) 222-228
8. Scala E., Pallotta S., Frezzolini A., Abeni D., Barbieri C., Sampogna F., et al. Cytokine and chemokine levels in systemic sclerosis: Relationship with cutaneous and internal organ involvement. Clin Exp Immunol 138 (2004) 540-546
9. Antonelli A., Ferri C., Fallahi P., Ferrari S.M., Giuggioli D., Colaci M., et al. CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis-a longitudinal study. Rheumatology (Oxford) 47 (2008) 45-49
10. Carulli M.T., Handler C., Coghlan J.G., Black C.M., and Denton C.P. Can CCL2 serum levels be used in risk stratification or to monitor treatment response in systemic sclerosis?. Ann Rheum Dis 67 (2008) 105-109
11. Yamamoto T., Eckes B., Hartmann K., and Krieg T. Expression of monocyte chemoattractant protein-1 in the lesional skin of systemic sclerosis. J Dermatol Sci 26 (2001) 133-139
12. Yamamoto T., Eckes B., and Krieg T. High expression and autoinduction of monocyte chemoattractant protein-1 in scleroderma fibroblasts. Eur J Immunol 31 (2001) 2936-2941
13. Distler J.H., Jungel A., Caretto D., Schulze-Horsel U., Kowal-Bielecka O., Gay R.E., et al. Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. Arthritis Rheum 54 (2006) 214-225
14. Muhlbauer M., Bosserhoff A.K., Hartmann A., Thasler W.E., Weiss T.S., Herfarth H., et al. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 125 (2003) 1085-1093
15. Flores-Villanueva P.O., Ruiz-Morales J.A., Song C.H., Flores L.M., Jo E.K., Montano M., et al. A functional promoter polymorphism in monocyte chemoattractant protein-1 is associated with increased susceptibility to pulmonary tuberculosis. J Exp Med 202 (2005) 1649-1658
16. Maruyama-Furuta N., Yano Y., Gabazza E.C., Suematsu M., Matsumoto K., Akatsuka H., et al. Monocyte chemoattractant protein-1 promoter -2518 polymorphism is associated with post-challenge insulin and glucose levels in non-diabetic Japanese subjects. Diabetes Res Clin Pract 78 (2007) 208-210
17. Karrer S., Bosserhoff A.K., Weiderer P., Distler O., Landthaler M., Szeimies R.M., et al. The -2518 promotor polymorphism in the MCP-1 gene is associated with systemic sclerosis. J Invest Dermatol 124 (2005) 92-98
18. Carulli M.T., Spagnolo P., Fonseca C., Welsh K.I., duBois R.M., Black C.M., and Denton C.P. Single-nucleotide polymorphisms in CCL2 gene are not associated with susceptibility to systemic sclerosis. J Rheumatol 35 (2008) 839-844
19. Navratilova Z., Lukac J., Mrazek F., Kriegova E., Bucova M., Bosak V., and Petrek M. MCP-1 -2518 A/G single nucleotide polymorphism in Slovak patients with systemic sclerosis. Mediators Inflamm (2008) 204063
20. LeRoy E.C., Black C., Fleischmajer R., Jablonska S., Krieg T., Medsger Jr. T.A., et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 15 (1988) 202-205
21. Matucci-Cerinic M., D'Angelo S., Denton C.P., Vlachoyiannopoulos P., and Silver R. Assessment of lung involvement. Clin Exp Rheumatol 21 3 Suppl 29 (2003) S19-S23
22. Miller S.A., Dykes D.D., and Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16 (1988) 1215
23. Allanore Y., Borderie D., Airo P., Guiducci S., Czirjak L., Nasonov E.L., et al. Lack of association between three vascular endothelial growth factor gene polymorphisms and systemic sclerosis: Results from a multicenter EUSTAR study of European Caucasian patients. Ann Rheum Dis 66 (2007) 257-259
24. Wipff J., Giraud M., Sibilia J., Mouthon L., Meyer O., Tiev K., et al. Polymorphic markers of the fibrillin-1 gene and systemic sclerosis in European Caucasian patients. J Rheumatol 35 (2008) 643-649